Signaling pathway analysis, molecular docking study and in vitro anticancer screening were performed on chosen H-RasP21, 721P and liver cancer cell lines (HepG2), respectively.
Signaling pathway analysis, molecular docking study and in vitro anticancer screening were performed on chosen H-RasP21, 721P and liver cancer cell lines (HepG2), respectively.
Signaling pathway analysis, molecular docking study and in vitro anticancer screening were performed on chosen H-RasP21, 721P and liver cancer cell lines (HepG2), respectively.
We suggest that B-lymphocyte surface antigen studies and a BTK mutation analysis should be performed in familial patients with selective IgM deficiency to rule out atypical XLA.